Case File
efta-01392933DOJ Data Set 10OtherEFTA01392933
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01392933
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
Special Statement for
Uncovered Option Writers
Account No.
N4G024968
Account Name
Deutsche Bank Alex. Brown
1. Dnot or• of Deatacte Sark Stant- Frc
Jeffrey Epstein
a
There are special risks associated with uncovered option writing which expose the investor to potentially significant loss. I understand
that this type of strategy may not be suitable for alt customers approved for options transactions. I also understand each of the
following:
1. The potential loss of uncovered call writing is unlimited, since there is no upper limit on a stock's price and the loss to a writer of
an uncovered call equals Mistook price minus the exercise price. The writer of an uncovered call is in an extremely risky
position, and may incur largo losses if the value of the underlying instrument increases above the exercise price. Such a loss can
exceed the equity in the call writer's account.
2. The potential loss from writing uncovered put options 's also substantial. The writer of an uncovered put option bears a risk of
loss if the value of the underlying instrument declines below the exercise price. However, since stock prices cannot be lower than
zero, the maximum loss is equal to the strike price of the pia sold less the premium received for that put. Such loss could be
substantial if there is a significant decline in the value of the underlying instrument and cart exceed the equity in the put writer's
account.
3. For combination writing, where the investor writes both a put and a call on the same underlying instrument, the potential risk is
unlimited and can exceed the equity in the Option writer's account.
4. Uncovered option writing is thus suitable only for the knowledgeable investor who understands the risks, has the financial capacity
and willingness to incur potentially substantial losses, and has sufficient liquid assets to meet applicable margin requirements. In
this regard, if the value of the underlying instrument moves against an uncovered writer's options position, the investor's broker
may request significant additional margin payments. If an investor does not make such margin payments, the broker may liquidate
stock or options positions in the investor's account, with little or no poor notice in accordance with the investor's margin
agreement.
5. The option writer may not be able to rely on the secondary market. If a secondary market in options were to become unavailable,
investors could not engage in closing transactions, and an option writer would remain obligated until expiration or assignment.
6. The writer of an American-style option is subject to being assigned an exercise at any time after he has written the option until
the option expires. By contrast, the writer of a European-style option is subject to exercise assignment only during the exercise
period.
NOTE: It is expected that the personts) signing below will read the booklet entitled Characteristics and Risks of Standardized Options
available from your broker. Particular attention is directed to the chapter entitled "Risks of Buying and Writing Options." This
statement is not intended to enumerate all of the risks entailed in writing uncovered options.
I have read and understand the above statement regarding the special risks associated with uncovered option writing and
represent that such trading is suitable in light of my investment objectives, which include speculation. as well as my
financial situation, risk
and knowledge. I understand that you will rely on the representations I have made herein
and in the Option
cement a d Approval Form I provided to_you in determining whether to approve my account for the
options strategi
have elects and I hereby c
ruth and accuracy of such statements.
Signed
Date
I D(A it II "N
Signed
Date
Signed
Date
Signed
Date
Signed
Date
Approved for:
‘covered Calls
iil'<incovered Puts
ROP/Manager Approval:
Date.
VaA
08-D3AB-0126 OM la A rn)Cs)
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
CONFIDENTIAL
DB-SDNY-0098253
SDNY_GM_00244437
EFTA01392933
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.